$ACOG developing ALS and Dementia treatment I'm always happy to put my money in a company that is going to do good in the world as well as do good on the market. Alpha Cognition Inc. ( $ACOG.V ACOGF ) is in the clinical stages of developing treatments for Alzheimer's Disease, ALS, and other under-served neurodegenerative diseases.
The two main drugs they are developing are ALPHA-1062 and ALPHA-602:
-
Alpha-1062 is very similar to a drug that was developed by J&J and approved in the mid-2000s but $ACOG's version is optimized to minimize side effects.
-
Alpha-602 is a progranulin gene therapy drug that has been shown to help with a number of disease states and could possibly become a curative option for ALS.
From a financial POV $ACOG is looking solid, having gained $14.4M from their Canadian IPO (which they intend to use for commercialization of ALPHA-1062 and ALPHA-602)
$ACOG is slightly down today trading at $1.12 (down 2.6%) so it could be a good time to get in.
https://www.alphacognition.com/